Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)

PHASE3CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 23, 2021

Primary Completion Date

November 20, 2022

Study Completion Date

November 20, 2022

Conditions
Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS)
Interventions
DRUG

Methylprednisolone sodium succinate 10 mg/kg intravenously

Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)

BIOLOGICAL

Human normal immunoglobulin (IVIg)

Human normal immunoglobulin (IVIg) 2g/kg intravenously as a single dose in line with guidance for dosing and administration in Kawasaki disease

Trial Locations (10)

1752

Department of Pediatrics, Cantonal Hospital Fribourg, Villars-sur-Glâne

3010

Department of Pediatrics, University of Bern, Bern

4056

University of Basel Children's Hospital, Basel

5001

Cantonal Hospital Aarau, Department of Paediatrics, Aarau

6000

Department of Pediatrics, Cantonal Hospital Luzern, Lucerne

6500

Ente Ospedaliero Cantonale Ticino (EOC) Pediatrica, Bellinzona

8032

University Children's Hospital Zuerich, Zurich

9006

Children's Hospital of Eastern Switzerland, Sankt Gallen

Unknown

Department of Child, Woman and, Adolescent Medecine, Geneva University Hospitals and Faculty of Medicine, Geneva

Department of Pediatrics,University Hospital of Lausanne (CHUV), Lausanne

All Listed Sponsors
collaborator

SwissPedNet

UNKNOWN

lead

University Children's Hospital Basel

OTHER